PPC
AGIO icon

Park Place Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Park Place Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-72
Closed -$2.37K – 827
2024
Q4 		$2.37K Hold
72
– – ﹤0.01% 714
2024
Q3 		$3.2K Hold
72
– – ﹤0.01% 730
2024
Q2 		$3.1K Hold
72
– – ﹤0.01% 739
2024
Q1 		$2.1K Buy
+72
New +$1.93K ﹤0.01% 819

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Park Place Capital's AGIO Position: Q1 2025 in Review

Park Place Capital sold out of Agios Pharmaceuticals (AGIO) in Q1 2025, closing a stake of 72 shares — an estimated $2.37K sold.

Park Place Capital first reported a position in AGIO in Q1 2024 and held it in 4 quarters. The position peaked at $3.2K in Q3 2024. 220 funds tracked by Wall St. Rank hold AGIO as of Q1 2025.

  • Park Place Capital reported no remaining Agios Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Park Place Capital sold 72 Agios Pharmaceuticals shares in Q1 2025, an estimated $2.37K.
  • Park Place Capital first reported a position in Agios Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Park Place Capital's Agios Pharmaceuticals position peaked at $3.2K in Q3 2024.
  • 220 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2025.

Based on Park Place Capital's 13F filing for Q1 2025, filed 24 Apr 2025.